Samsung Biologics is a full service CDMO focused on the development and manufacture of biologics for the improvement of global healthcare. Established in 2011, Samsung Biologics offers a full range of solutions for the biopharmaceutical industry, including cell line process and analytical method development, analytical services, and bulk cGMP manufacturing of drug substance and drug product from clinical to commercial scale. Based in Incheon, South Korea, Samsung Biologics’ four manufacturing facilities are optimized for the production of monoclonal and recombinant drug substance and drug product, and operate with strict adherence to quality assurance, quality control and global regulatory compliance standards. Samsung Biologics' Plant 4, the world's largest single biomanufacturing plant, began GMP operations in 2022.